Drug Development

Parents hold their four-year-old daughter, who received Zolgensma for spinal muscular atrophy as an infant.
Blog Post

A Revolutionary Decade for Spinal Muscular Atrophy Therapies

By Chris Anselmo | August 1, 2024
Blog Post

MDA Ambassador Guest Blog: Finding Hope and Optimism in New Treatments

By Chase Rankin | June 4, 2024
Woman in electric wheelchair waits for consultation with doctor in clinic waiting area. Nurse invites patient with disability on procedures. Medical staff and people in modern medical facility lobby.
Blog Post

Treatment Options for Autoimmune Neuromuscular Diseases

By Patrick Sullivan | May 17, 2024
Illustration of digital health technologies
Featured Article

Can Wearables and Smartphones Make Clinical Trials Better?

By Andrew Zaleski | May 9, 2024
A group of people from neuromuscular advocacy organizations gathered at the 2024 MDA Clinical & Scientific Conference.
Featured Article

Understanding Titinopathies

By Myrna Traylor | May 9, 2024
Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis - 3d illustration
Blog Post

Simply Stated: Updates in SELENON-Related Myopathy

By Sujatha Gurunathan | May 7, 2024
Blog Post

Episode 39- Behind the Scenes: A Look at the Science and Research for New Treatments

By MDA Staff | April 1, 2024
Blog Post

FDA’s Approval of Duvyzat (givinostat) Offers New Hope to People Living with Duchenne Muscular Dystrophy

By MDA Staff | March 21, 2024
wooden blocks spell out the word content with word bubbles above that say news and stories and photos and blog
Blog Post

In Case You Missed It…

By MDA Staff | March 8, 2024
Illustration of a black metal pipeline on a yellow background
Featured Article

What Is the Drug Development Pipeline?

By Amy Bernstein | February 12, 2024